• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Sucampo Pharmaceuticals Appoints Kathryn De Santis As Vice President, Investor Relations and Corporate Communications

Posted on: Monday, 25 August 2008, 18:00 CDT

Sucampo Pharmaceuticals, Inc., (NASDAQ:SCMP), today announced that it has named Kathryn de Santis as its Vice President, Investor Relations and Corporate Communications.

Ms. de Santis brings to Sucampo extensive investor relations and communications experience. For the past 11 years, she served as Director of Investor Relations and Corporate Communications at Human Genome Sciences, Inc. (HGS). Prior to joining HGS, Ms. de Santis served as a vice president at Dewe Rogerson, Inc. (now Citigate Dewe Rogerson), where she was responsible for developing and implementing investor and financial media programs for development stage biotechnology companies. Ms. de Santis also served as an account supervisor at Burns McClellan, New York, where she was responsible for the communications needs of biotechnology companies. Ms. de Santis holds an MBA in Marketing Management from Pace University's Lubin Graduate School of Business, in White Plains, New York, and a B.A. in English Literature from Molloy College, in Rockville Centre, New York.

"I am very pleased to welcome Kate to Sucampo. We look forward to utilizing her extensive expertise in the life sciences industry as we shape our investor relations and corporate communications' program. She will be instrumental in helping us to increase the investment community's knowledge of the science behind Sucampo's products and pipeline, and the novel technology of prostones," said Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals' chairman and chief executive officer.

Sucampo Pharmaceuticals, Inc., a specialty biopharmaceutical company based in Bethesda, MD, focuses on the development and commercialization of medicines based on prostones. The therapeutic potential of prostones, which are bio-lipids that occur naturally in the human body, was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals' Chairman and Chief Executive Officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding Chief Executive Officer and Advisor, International Business Development.

Sucampo Pharmaceuticals is marketing AMITIZA(R) (lubiprostone) in the U.S. and is developing the drug for additional indications with large potential markets. In addition, the company has a robust pipeline of compounds with the potential to target unmet medical conditions affecting millions of patients worldwide. Sucampo Pharmaceuticals has two wholly owned subsidiaries: Sucampo Pharma Europe, Ltd., headquartered in Oxford, UK, with a branch office in Basel, Switzerland, and Sucampo Pharma, Ltd., located in Tokyo and Osaka, Japan. To learn more about Sucampo Pharmaceuticals and its products, visit www.sucampo.com.

AMITIZA(R) is a registered trademark of Sucampo Pharmaceuticals, Inc.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Sucampo Pharmaceuticals are forward-looking statements made under the provisions of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors described in Sucampo Pharmaceuticals' filings with the Securities and Exchange Commission (SEC), including the annual report on Form 10-K for the year ended December 31, 2007 and other periodic reports filed with the SEC. Any forward-looking statements in this press release, including statements regarding the expansion in the number of indications addressed by AMITIZA(R) 8mcg, our ability to drive AMITIZA(R) sales growth and build greater brand awareness among patients and physicians, and the future success of our ongoing preclinical studies and clinical trials, represent Sucampo Pharmaceuticals' views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Sucampo Pharmaceuticals anticipates that subsequent events and developments will cause its views to change. However, while Sucampo Pharmaceuticals may elect to update these forward-looking statements publicly at some point in the future, Sucampo Pharmaceuticals specifically disclaims any obligation to do so, whether as a result of new information, future events or otherwise.

Source: Business Wire

More News in this Category